Quality of Life and Radiotherapy Complications of Chinese Nasopharyngeal Carcinoma Patients at Different 3DCRT Stages

Gu, Mo Fa; Su, Yong; Chen, Xin Lin; He, Wei; He, Zhenyu; Li, Jian Jun; Chen, Miao Qiu; Mo, Chuan Wei; Xu, Qing; Diao, Yuan Ming

doi:10.7314/apjcp.2012.13.1.075

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies used the Functional Assessment of Cancer Therapy-General (FACT-G) scale, the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) module [14, 15], and the Functional Assessment of Cancer Therapy-Nasopharyngeal (FACT-NP) subscale [16]. Other studies used the MOS 36-item short-form health survey (SF-36) [17, 18] and the University of Washington Quality of Life Questionnaire [19]. Recently, an NPC-specific scale (QoL-NPC) was developed to assess the physical functioning and health status of Chinese NPC patients [20].…”

Section: Discussionmentioning

confidence: 99%

Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy

et al. 2017

View full text Add to dashboard Cite

The purpose of this study was to compare the quality of life (QoL) of stage II nasopharyngeal carcinoma (NPC) patients treated with radiotherapy (RT) versus concurrent chemoradiotherapy (CCRT). In a cross-sectional study, these patients were treated with RT (n = 55) or CCRT (n = 51) between June 2008 and June 2013. For all subjects, disease-free survival was more than 3 years. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questions and the Head and Neck 35 (EORTC QLQ-H&N35) questions. RT had better outcomes than CCRT for global QoL, functional scales, symptom scales of fatigue and insomnia, financial problems, and weight gain. Survivors receiving 1 cycle of concurrent chemotherapy had worse QoL outcomes than survivors receiving 2 cycles of concurrent chemotherapy. Patients receiving 3 cycles of concurrent chemotherapy had the best QoL outcomes. Thus, CCRT adversely affects the QoL of patients with stage II NPC as compared to radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Radiotherapy can also cause radiation damage to normal tissues in the radiation part, resulting in different degrees of short-term and long-term radiation complications [ 8 ]. NPC patients receiving radiation therapy may suffer from complications including radio-pulmonary lesion, radiation esophagitis, radiodermatitis, xerostomia, radioactive parotitis and so on [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy

Zhang

Zha

et al. 2022

BMC Oral Health

View full text Add to dashboard Cite

Background This study was to evaluate the predictors of xerostomia and Grade 3 xerostomia in locoregionally advanced nasopharyngeal carcinoma (NPC) patients receiving radical radiotherapy and establish prediction models for xerostomia and Grade 3 xerostomia based on the predictors. Methods Totally, 365 patients with locoregionally advanced NPC who underwent radical radiotherapy were randomly divided into the training set (n = 255) and the testing set (n = 110) at a ratio of 7:3. All variables were included in the least absolute shrinkage and selection operator regression to screen out the potential predictors for xerostomia as well as the Grade 3 xerostomia in locoregionally advanced NPC patients receiving radical radiotherapy. The random forest (RF), a decision tree classifier (DTC), and extreme-gradient boosting (XGB) models were constructed. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), area under the curve (AUC) and accuracy were analyzed to evaluate the predictive performance of the models. Results In the RF model for predicting xerostomia, the sensitivity was 1.000 (95%CI 1.000–1.000), the PPV was 0.990 (95%CI 0.975–1.000), the NPV was 1.000 (95%CI 1.000–1.000), the AUC was 0.999 (95%CI 0.997–1.000) and the accuracy was 0.992 (95%CI 0.981–1.000) in the training set. The sensitivity was 0.933 (95%CI 0.880–0.985), the PPV was 0.933 (95%CI 0.880–0.985), and the AUC was 0.915 (95%CI 0.860–0.970) in the testing set. Hypertension, age, total radiotherapy dose, dose at 50% of the left parotid volume, mean dose to right parotid gland, mean dose to oral cavity, and course of induction chemotherapy were important variables associated with the risk of xerostomia in locoregionally advanced NPC patients receiving radical radiotherapy. The AUC of DTC model for predicting xerostomia was 0.769 (95%CI 0.666–0.872) in the testing set. The AUC of the XGB model for predicting xerostomia was 0.834 (0.753–0.916) in the testing set. The RF model showed the good predictive ability with the AUC of 0.986 (95%CI 0.972–1.000) in the training set, and 0.766 (95%CI 0.626–0.905) in the testing set for identifying patients who at high risk of Grade 3 xerostomia in those with high risk of xerostomia. Conclusions An RF model for predicting xerostomia in locoregionally advanced NPC patients receiving radical radiotherapy and an RF model for predicting Grade 3 xerostomia in those with high risk of xerostomia showed good predictive ability.

show abstract

“…These side effects obviously have a serious impact on the health-related quality of life (QOL) in NPC patients. The QOL of the NPC patients has been widely studied with the following inventories: the European Organization for the Research and Treatment of Cancer Core QOL questionnaire (QLQ-C30) and head and neck module (QLQ-H&N35) [ 4 , 5 ]; the MOS 36-item short-form health survey (SF-36) [ 6 , 7 ]; The University of Washington Quality of Life [ 8 ]; the Functional Assessment of Cancer Therapy-General Scale (FACT-G) and head and neck module (FACT-H&N) [ 9 , 10 ]; and the functional assessment of cancer therapy-nasopharyngeal (FACT-NP) [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2)

Cheng

et al. 2016

Health Qual Life Outcomes

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim was to develop and validate the quality of life scale for nasopharyngeal carcinoma (NPC) patients, the QOL-NPC (version 2), a specific instrument to measure quality of life for NPC patients.MethodsThe QOL-NPC was developed and validated according to standard procedures. The patients were assessed using the QOL-NPC, FACT-G, and FACT-H&N. Classical test theory was used to evaluate the reliability, validity, and responsiveness of the QOL-NPC.ResultsA total of 487 patients (97.4 %) completed the questionnaire. The QOL-NPC comprised four domains, as follows: physical function (eight items); psychological function (five items); social function (five items); and side effects (eight items). All of the items had a lower proportion of missing data. Cronbach's alpha values of the domains ranged from 0.72 to 0.84. The split-half reliability coefficients ranged from 0.77 to 0.84. All of the intra-class correlation coefficients were > 0.8. The normed fit index, non-normed fit index, and comparative fit index were >0.89. The root mean square error of approximation was 0.097, with a 90 % confidence interval (0.093, 0.100). The domain scores of the QOL-NPC were significantly correlated with the FACT-G and FACT-H&N (P < 0.05). All of the domain scores of patients using different amounts of radiotherapy were significantly different (P < 0.001). All domain scores decreased at the completion of radiotherapy, with effect sizes ranging from −0.82 to −0.22.ConclusionsThe QOL-NPC is valid for measuring QOL with good reliability, validity, and responsiveness. The QOL-NPC is recommended to measure the QOL for Chinese NPC patients.

show abstract

Quality of Life and Radiotherapy Complications of Chinese Nasopharyngeal Carcinoma Patients at Different 3DCRT Stages

Cited by 4 publications

References 21 publications

Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy

Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy

A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy

Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2)

Contact Info

Product

Resources

About